TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12477510

Group type: EXPERIMENTAL
Intervention: PCBs and PEs exposure in infertile men
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (32 men with normal semen analyses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Total motile sperm counts in infertile men
Number of subjects: 21
Study: 9661604

Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐I concentration
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐II concentration
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Serum IGF‐I concentration
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐I
Number of subjects: 533
Study: 7660438

Group type: EXPERIMENTAL
Intervention: Oral iron (60mg elemental iron per day)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 2468963

Group type: EXPERIMENTAL
Intervention: Higher daily dosages of enalapril (40 mg and, when necessary, 60 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 20 mg/day enalapril and hydrochlorothiazide (25 mg/day and, when necessary, 50 mg)
Number of subjects: 46
Study: 544571

Group type: EXPERIMENTAL
Intervention: Abdominopelvic irradiation using a moving-strip technique, 2250 rad in 10 fractions, starting with pelvic irradiation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic irradiation alone or followed by chlorambucil therapy.
Number of subjects: 0
Study: 30370752

Group type: EXPERIMENTAL
Intervention: LATE program (land-based and aquatic trunk exercises)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 29
Study: 28176305

Group type: EXPERIMENTAL
Intervention: Abdominal cerclage
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (high or low transvaginal cerclage)
Number of subjects: 67
Study: 25460265

Group type: EXPERIMENTAL
Intervention: Masked images of spiders (VBE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Masked images of flowers (Control)
Number of subjects: 86
Study: 23481528

Group type: EXPERIMENTAL
Intervention: Same-day discharge (n=150)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Next-day discharge (n=148)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 298
Study: 20672243

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 19169146

Group type: EXPERIMENTAL
Intervention: Propofol in combination with meperidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 200
Study: 19776569

Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste (A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste followed by professional flossing (B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste followed by professional flossing and rinsing with NaF mouthwash (C)
Number of subjects: 20
Study: 16368051

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day (O group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day (F group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid plus micronised fenofibrate 200 mg/day (OF group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 89
Study: 12507240

Group type: EXPERIMENTAL
Intervention: HA‐coated threaded implants
Number of subjects: 120

Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 120
Study: 9814501

Group type: EXPERIMENTAL
Intervention: RET/PTC rearrangements in occult papillary thyroid microcarcinomas
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RET/PTC rearrangements in clinically evident tumors
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry correlation with RT-PCR
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RET/PTC expression prevalence
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diversity of RET/PTC profiles in multifocal disease
Number of subjects: 21
Study: 9098296

Group type: EXPERIMENTAL
Intervention: 1% tetracaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 2713216

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (120 mg orally)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 887644

Group type: EXPERIMENTAL
Intervention: Thioridazine (Melleril-Sandoz)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11368483

Group type: EXPERIMENTAL
Intervention: Johnstone pressure splints (JPSs) combined with Bobath's neurodevelopmental therapy (NDT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NDT alone
Number of subjects: 34
Study: 30986795

Group type: EXPERIMENTAL
Intervention: Self-collection of vaginal swabs without nurse assistance
Number of subjects: 96

Group type: COMPARATOR
Intervention: Self-collection of vaginal swabs with nurse assistance
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-collection of vaginal swabs (both arms)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis testing
Number of subjects: 96
Study: 29388901

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 6
Study: 26896345

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 12.5 μg/kg (D12.5)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 μg/kg (D25)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 μg/kg and MK‐467 600 μg/kg (D25M600)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MK‐467 300 μg/kg (M300)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MK‐467 in D25M600
Number of subjects: 7
Study: 25364817

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 0
Study: 22490161

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 78
Study: 20379030

Group type: EXPERIMENTAL
Intervention: Beautifil II (containing S-PRG filler)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clearfil AP-X
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtek Z250
Number of subjects: 0
Study: 17272731

Group type: EXPERIMENTAL
Intervention: Low-dose prophylactic haloperidol treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 16136045

Group type: EXPERIMENTAL
Intervention: IL-2 with histamine dihydrochloride (HDC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 104
Study: 12433233

Group type: EXPERIMENTAL
Intervention: bupropion SR (150 mg for week 1, 300 mg for weeks 2 to 5)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: bupropion SR
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 10453828

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg four hourly (to a maximum of four doses)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dinoprostone gel 1 mg six hourly (to a maximum of three doses)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 211
Study: 8535660

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS)
Number of subjects: 30
Study: 2199281

Group type: EXPERIMENTAL
Intervention: Insulin analogues (B9Asp + B27Glu or B10Asp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0
Study: 69194

Group type: EXPERIMENTAL
Intervention: Tetramisole every 4 months
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 30838777

Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for treatment efficacy in marker-positive subpopulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for treatment efficacy in marker-negative patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for assessing marker accuracy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical testing strategies based on probabilities of asserting treatment efficacy
Number of subjects: 0
Study: 29442544

Group type: EXPERIMENTAL
Intervention: LEV with supplemental pyridoxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: LEV only (control group)
Number of subjects: 0
Study: 27115337

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 29
Study: 23742666

Group type: EXPERIMENTAL
Intervention: Expressive writing (writing for 20 minutes on four occasions about deepest thoughts and feelings regarding their most stressful/traumatic event)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control topic (writing about a control topic)
Number of subjects: 116
Study: 22591134

Group type: EXPERIMENTAL
Intervention: Training for YHC professionals to increase self-efficacy and skills in discussing weight issues
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Improved communication skills for YHC professionals
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased parental awareness of child's overweight
Number of subjects: 16
Study: 21126973

Group type: EXPERIMENTAL
Intervention: FFR-guided percutaneous coronary intervention
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention
Number of subjects: 1005
Study: 17616452

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 120 microg/day p.o.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telmisartan (TS) 40 mg/day p.o.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) plus Telmisartan (TS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 80
Study: 15812750

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 35
Study: 11158473

Group type: EXPERIMENTAL
Intervention: Cys‐LT receptor antagonists (Cys‐LTRA) such as montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LT modifiers
Number of subjects: 0
Study: 9554431

Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study: 7930028

Group type: EXPERIMENTAL
Intervention: Piroximone infusion at 5 micrograms/kg/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piroximone infusion at 10 micrograms/kg/min
Number of subjects: 12
Study: 3276999

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg (n = 10)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 mg (n = 4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg (n = 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine detoxification (successful)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine detoxification (failures)
Number of subjects: 16
Study: 31247017

Group type: EXPERIMENTAL
Intervention: Laughter therapy (4 sessions, once every two weeks for seven weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 56
Study: 28325221

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment (IHT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 25897569

Group type: EXPERIMENTAL
Intervention: 8-hour nightly CPAP treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 39
Study: 23732713

Group type: EXPERIMENTAL
Intervention: Aspirin (n = 386)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Dalteparin (n = 400)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Composite of all VTE and clinically significant bleeding events (Aspirin vs Dalteparin)
Number of subjects: 778
Study: 21447945

Group type: EXPERIMENTAL
Intervention: Ultrafiltration group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 18416085

Group type: EXPERIMENTAL
Intervention: Fuscoporia obliqua
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (diet-treated type 2 diabetic patients)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (age- and sex-matched controls)
Number of subjects: 14
Study: 16865013

Group type: EXPERIMENTAL
Intervention: dorzolamide 1% 3 times daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: carteolol hydrochloride 2% twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: latanoprost-dorzolamide combination
Number of subjects: 64

Group type: COMPARATOR
Intervention: latanoprost-carteolol combination
Number of subjects: 64
Study: 12627729

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (6 g nightly, adjustable between 3 to 9 g)
Number of subjects: 118
Study: 10846514

Group type: EXPERIMENTAL
Intervention: Enriched foods
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-enriched foods
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (neither enriched foods nor exercise)
Number of subjects: 143
Study: 9400511

Group type: EXPERIMENTAL
Intervention: 100 micrograms/day folic acid
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 200 micrograms/day folic acid
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 400 micrograms/day folic acid
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 7959385

Group type: EXPERIMENTAL
Intervention: Epididymal fine needle aspiration (EFNA)
Number of subjects: 17
Study: 3296628

Group type: EXPERIMENTAL
Intervention: High protein intake (3‐5 g/kg bw for 24 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Uncontrolled protein intake (2‐2.5 g/kg bw)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low protein intake (1.2 g/kg bw for 12 days)
Number of subjects: 18
Study: 29703287

Group type: EXPERIMENTAL
Intervention: Intracameral combination of 2 mydriatics and 1 anesthetic (Mydrane)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Topical regimen (control group)
Number of subjects: 730
Study: 27855085

Group type: EXPERIMENTAL
Intervention: Electroacupuncture pretreatment followed by 4 cycles of letrozole
Number of subjects: 384

Group type: COMPARATOR
Intervention: Letrozole alone (control group)
Number of subjects: 384
Study: 24656727

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 23
Study: 23516294

Group type: EXPERIMENTAL
Intervention: Emotional working memory training for 20 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 0
Study: 20586697

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (group and individual treatment, dietary counseling, cognitive-behavioral therapy)
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies (metformin, fenfluramine, sibutramine, topiramate, reboxetine)
Number of subjects: 2375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2375
Study: 18078958

Group type: EXPERIMENTAL
Intervention: Stenting of the ureteroileal anastomosis
Number of subjects: 54

Group type: COMPARATOR
Intervention: No stenting of the ureteroileal anastomosis
Number of subjects: 54
Study: 16888042

Group type: EXPERIMENTAL
Intervention: Overtrained group (OT) performing 10 x 1 at 100% 1 RM daily for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (Con) performing normal training 2 days/week
Number of subjects: 16
Study: 11822985

Group type: EXPERIMENTAL
Intervention: CNS-directed therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current chemotherapy approaches
Number of subjects: 0
Study: 9659069

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 2303

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 2303

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 2303

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2303
Study: 9118364

Group type: EXPERIMENTAL
Intervention: Radiofrequency needle ablation (TUNA technique)
Number of subjects: 15
Study: 2497058

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg tid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14468

Group type: EXPERIMENTAL
Intervention: Atenolol (600 mg daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (15 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6163829

Group type: EXPERIMENTAL
Intervention: Dimethylglycine (DMG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 30616596

Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 28673368

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administration
Number of subjects: 534

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 534
Study: 26843155

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (SQ-LNSs)
Number of subjects: 869
Study: 23771835

Group type: EXPERIMENTAL
Intervention: Resistance prior to aerobic training (RA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistance after aerobic training (AR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both RA and AR
Number of subjects: 26
Study: 21737178

Group type: EXPERIMENTAL
Intervention: CHG gel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CHG disk
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 19346443

Group type: EXPERIMENTAL
Intervention: GTN (0.8 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PETN (80 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GTN plus LA (600 mg)
Number of subjects: 8
Study: 17688053

Group type: EXPERIMENTAL
Intervention: Fibrin glue injection after aspiration of more than 15 ml of CSF (Group A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fibrin glue injection without CSF aspiration (Group B)
Number of subjects: 31
Study: 15599679

Group type: EXPERIMENTAL
Intervention: Medical health education lesson
Number of subjects: 1911

Group type: COMPARATOR
Intervention: Control group (no health education lesson)
Number of subjects: 1911
Study: 12470133

Group type: EXPERIMENTAL
Intervention: Cigarette-related cues exposure (watching a videotape that presented cigarette-related cues and handling a cigarette)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neutral object exposure (watching an educational (nature) videotape and handling a neutral object (pen))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cigarette-related cues exposure
Number of subjects: 40
Study: 9718197

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (beclomethasone or budesonide) > or = 1500 microg/day for at least 12 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prior oral glucocorticoid exposure (OG)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (IG)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Total duration of OG
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Bone formation markers
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Adrenal androgen suppression
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-dose IG
Number of subjects: 53
Study: 8110727

Group type: EXPERIMENTAL
Intervention: Crystalloid (0.9% normal saline)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Colloid (5% human serum albumin)
Number of subjects: 107
Study: 2508527

Group type: EXPERIMENTAL
Intervention: Levamisole for 8 weeks (L8 series)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Levamisole for 4 weeks (L4 series)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo only (L0 series)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Levamisole (both L4 and L8)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 504
Study: 776209

Group type: EXPERIMENTAL
Intervention: PGE2 1.0 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGE2 1.5 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGE2 2.0 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGE2 3.0 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGF2alpha 10.0 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PGF2alpha
Number of subjects: 230
Study: 30391370

Group type: EXPERIMENTAL
Intervention: 1-month training interval
Number of subjects: 167

Group type: COMPARATOR
Intervention: 3-month training interval
Number of subjects: 167

Group type: COMPARATOR
Intervention: 6-month training interval
Number of subjects: 167

Group type: COMPARATOR
Intervention: 12-month training interval
Number of subjects: 167
Study: 27265488

Group type: EXPERIMENTAL
Intervention: 10 min passive rest
Number of subjects: 11

Group type: COMPARATOR
Intervention: 20 min passive rest
Number of subjects: 11
Study: 24851793

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of pregabalin combined with a COX‐2 inhibitor
Number of subjects: 41

Group type: COMPARATOR
Intervention: COX‐2 inhibitor only (Control)
Number of subjects: 41
Study: 23146926

Group type: EXPERIMENTAL
Intervention: Ivabradine (10 mg)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Beta-blockers (bisoprolol 2.5 mg/day, carvedilol 12.5 mg/day, atenolol 50 mg/day)
Number of subjects: 238
Study: 22172779

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 80
Study: 19223709

Group type: EXPERIMENTAL
Intervention: Gelatin solutions
Number of subjects: 0
Study: 17122576

Group type: EXPERIMENTAL
Intervention: Midazolam (loading dose of 1 mg followed by continuous infusion of 0.5 mg/h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midazolam (as above)
Number of subjects: 24
Study: 15098969

Group type: EXPERIMENTAL
Intervention: Topical retinoids and antibiotics combination therapy
Number of subjects: 0
Study: 11676995

Group type: EXPERIMENTAL
Intervention: NPPV based on nocturnal oximetry studies suggesting oxygen desaturation <90% for one cumulative minute (early intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (NPPV based on FVC <50%)
Number of subjects: 20